Gamma Therapeutics, a product research and development company, will develop a host of new commercial products to address the need for point-of-care diagnostic testing and post-surgical therapy products in the fast growing cardiovascular disease (CVD) market.

The Company will develop its products from R&D, to patent and FDA regulatory approval, then license each product for manufacture, distribution and sales through non-exclusive and limited royalty-bearing licensing agreements with strategic business and channel sales partners. Gamma Therapeutics will bring its flagship product, the GammaCoeur Cardiovascular Disease Risk Assay, to market under licensing agreements with diagnostic test assay manufacturers, national and international distributors and laboratory test service providers.

Gamma Therapeutics, Inc. actively seeks research and development partnerships and collaborative scientific relationships.

Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.